New insights into the mechanism of action of amphetamines
- PMID: 17209801
- DOI: 10.1146/annurev.pharmtox.47.120505.105140
New insights into the mechanism of action of amphetamines
Abstract
Amphetamine is a psychostimulant commonly used to treat several disorders, including attention deficit, narcolepsy, and obesity. Plasmalemmal and vesicular monoamine transporters, such as the neuronal dopamine transporter and the vesicular monoamine transporter-2, are two of its principal targets. This review focuses on new insights, obtained from both in vivo and in vitro studies, into the molecular mechanisms whereby amphetamine, and the closely related compounds methamphetamine and methylenedioxymethamphetamine, cause monoamine, and particularly dopamine, release. These mechanisms include amphetamine-induced exchange diffusion, reverse transport, and channel-like transport phenomena as well as the weak base properties of amphetamine. Additionally, amphetamine analogs may affect monoamine transporters through phosphorylation, transporter trafficking, and the production of reactive oxygen and nitrogen species. All of these mechanisms have potential implications for both amphetamine- and methamphetamine-induced neurotoxicity, as well as dopaminergic neurodegenerative diseases.
Similar articles
-
Methamphetamine-induced alterations in monoamine transport: implications for neurotoxicity, neuroprotection and treatment.Addiction. 2007 Apr;102 Suppl 1:44-8. doi: 10.1111/j.1360-0443.2007.01771.x. Addiction. 2007. PMID: 17493052 Review.
-
The role of the plasmalemmal dopamine and vesicular monoamine transporters in methamphetamine-induced dopaminergic deficits.J Neurochem. 2007 May;101(4):883-8. doi: 10.1111/j.1471-4159.2006.04419.x. Epub 2007 Jan 23. J Neurochem. 2007. PMID: 17250674 Review.
-
The methamphetamine experience: a NIDA partnership.Neuropharmacology. 2004;47 Suppl 1:92-100. doi: 10.1016/j.neuropharm.2004.06.004. Neuropharmacology. 2004. PMID: 15464128 Review.
-
Dopamine-induced behavioral changes and oxidative stress in methamphetamine-induced neurotoxicity.Int Rev Neurobiol. 2009;88:43-64. doi: 10.1016/S0074-7742(09)88003-3. Int Rev Neurobiol. 2009. PMID: 19897074 Review.
-
Monoamine transporter as a target molecule for psychostimulants.Int Rev Neurobiol. 2009;85:29-33. doi: 10.1016/S0074-7742(09)85003-4. Int Rev Neurobiol. 2009. PMID: 19607959 Review.
Cited by
-
Co-targeting the kappa opioid receptor and dopamine transporter reduces motivation to self-administer cocaine and partially reverses dopamine system dysregulation.Sci Rep. 2024 Mar 18;14(1):6509. doi: 10.1038/s41598-024-53463-9. Sci Rep. 2024. PMID: 38499566 Free PMC article.
-
Series of (([1,1'-Biphenyl]-2-yl)methyl)sulfinylalkyl Alicyclic Amines as Novel and High Affinity Atypical Dopamine Transporter Inhibitors with Reduced hERG Activity.ACS Pharmacol Transl Sci. 2024 Jan 5;7(2):515-532. doi: 10.1021/acsptsci.3c00322. eCollection 2024 Feb 9. ACS Pharmacol Transl Sci. 2024. PMID: 38357284
-
Prevalence of the use of prescription stimulants as "study drugs" by UK university students: A brief report.Brain Behav. 2024 Feb;14(2):e3419. doi: 10.1002/brb3.3419. Brain Behav. 2024. PMID: 38346719 Free PMC article. Review.
-
Effects of congeners of amphetamine on the human heart.Naunyn Schmiedebergs Arch Pharmacol. 2024 Feb 10. doi: 10.1007/s00210-024-02983-2. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 38340182 Review.
-
Uncovering transcriptomic biomarkers for enhanced diagnosis of methamphetamine use disorder: a comprehensive review.Front Psychiatry. 2024 Jan 8;14:1302994. doi: 10.3389/fpsyt.2023.1302994. eCollection 2023. Front Psychiatry. 2024. PMID: 38260797 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
